Replies to post #190011 on Biotech Values

[dewophile]

I really don't think investors are too concerned with the 40mg at this point

why not? It's 65% of the market. Teva could even discount the 40mg to some degree to ease switches to QD generic and ease insurance pressure in general. This is TEVA we are talking about they will go to the mattresses to maintain share